Analysts Set Expectations for CGTX FY2026 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Equities researchers at Brookline Capital Markets lifted their FY2026 EPS estimates for Cognition Therapeutics in a research report issued to clients and investors on Thursday, November 5th. Brookline Capital Markets analyst F. Ahmed now expects that the company will earn ($0.20) per share for the year, up from their previous estimate of ($0.42). The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.30) per share. Brookline Capital Markets also issued estimates for Cognition Therapeutics’ Q4 2026 earnings at ($0.06) EPS.

Other research analysts have also issued reports about the company. Wall Street Zen lowered Cognition Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Cognition Therapeutics in a research note on Monday, September 21st. Finally, HC Wainwright restated a “buy” rating on shares of Cognition Therapeutics in a research note on Monday, October 5th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Cognition Therapeutics has an average rating of “Moderate Buy” and an average price target of $3.33.

Cognition Therapeutics Price Performance

NASDAQ CGTX opened at $0.69 on Tuesday. Cognition Therapeutics has a 12 month low of $0.55 and a 12 month high of $1.82. The stock has a 50 day moving average of $0.87 and a 200-day moving average of $1.05.

Cognition Therapeutics (NASDAQ:CGTX) last released its earnings results on Thursday, November 5th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03.

Institutional Trading of Cognition Therapeutics

Several hedge funds have recently added to or reduced their stakes in CGTX. BlackRock Inc. acquired a new position in Cognition Therapeutics in the 2nd quarter valued at $1,451,000. Renaissance Technologies LLC increased its position in Cognition Therapeutics by 15.2% during the 1st quarter. Renaissance Technologies LLC now owns 1,117,136 shares of the company’s stock worth $848,000 after buying an additional 147,623 shares during the period. Sigma Planning Corp lifted its holdings in shares of Cognition Therapeutics by 7.3% during the second quarter. Sigma Planning Corp now owns 362,265 shares of the company’s stock worth $417,000 after buying an additional 24,500 shares in the last quarter. Tocqueville Asset Management L.P. acquired a new stake in shares of Cognition Therapeutics during the second quarter worth $369,000. Finally, Texas Capital Bank Wealth Management Services Inc bought a new stake in shares of Cognition Therapeutics in the second quarter valued at about $165,000. 43.35% of the stock is owned by institutional investors and hedge funds.

About Cognition Therapeutics

Cognition Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s research centers on the sigma-2 receptor, also known as the sigma-2 receptor complex or PGRMC1, a target believed to play a role in the cellular mechanisms associated with synaptic dysfunction and neurodegeneration.

Cognition Therapeutics’ lead product candidate is CT1812, an orally administered small-molecule therapy designed to modulate the sigma-2 receptor complex.